Karuna Therapeutics Inc (KRTX)
196.88
+0.80 (+0.41%)
USD |
NASDAQ |
Jan 27, 16:00
196.74
-0.14 (-0.07%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 6.687B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 92.64% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 5.648 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
News
Headline
Wire
Time (ET)
MT Newswires
01/05 07:39
Yahoo
01/03 06:30
PR Newswire
12/29 14:13
Yahoo
12/17 07:08
Globe Newswire
12/15 09:51
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 02/24/2023* | -- | Results | Q4 2022 | -- | -2.30 | -- | |
| 11/03/2022 | -- | Results | Q3 2022 | -2.38 | -2.25 | -5.86% | |
| 08/08/2022 | -- | Results | Q2 2022 | -2.17 | -2.10 | -3.15% | |
| 05/05/2022 | -- | Results | Q1 2022 | -1.95 | -2.10 | 7.16% | |
| 02/24/2022 | -- | Results | Q4 2021 | -0.94 | -1.81 | 47.96% | |
| 11/04/2021 | -- | Results | Q3 2021 | -1.72 | -1.47 | -17.25% | |
| 08/05/2021 | -- | Results | Q2 2021 | -1.17 | -1.40 | 16.68% | |
| 05/06/2021 | -- | Results | Q1 2021 | -1.10 | -1.22 | 9.57% |
*Estimated Date/Time
Earnings
Profile
Edit
| Karuna Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by unmet medical needs. Its product candidate, KarXT is an oral modulator of muscarinic receptors that are located both in the central nervous system, or CNS, and various peripheral tissues. |
| URL | https://www.karunatx.com |
| Investor Relations URL | https://investors.karunatx.com/ |
| HQ State/Province | Massachusetts |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Mid Cap/Growth |
| Next Earnings Release | Feb. 24, 2023 (est.) |
| Last Earnings Release | Nov. 03, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of January 27, 2023.
Fundamentals
2017
2018
2019
2020
2021
4.00
2.00
1.00
| Revenue (TTM) | -- |
| Total Expenses (TTM) | 275.15M |
| Net Income (TTM) | -228.08M |
| Total Assets (Quarterly) | 1.228B |
| Total Liabilities (Quarterly) | 44.46M |
| Shareholders Equity (Quarterly) | 1.184B |
| Cash from Operations (TTM) | -156.25M |
| Cash from Investing (TTM) | -321.80M |
| Cash from Financing (TTM) | 854.14M |
Ratings
Profile
Edit
| Karuna Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by unmet medical needs. Its product candidate, KarXT is an oral modulator of muscarinic receptors that are located both in the central nervous system, or CNS, and various peripheral tissues. |
| URL | https://www.karunatx.com |
| Investor Relations URL | https://investors.karunatx.com/ |
| HQ State/Province | Massachusetts |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Mid Cap/Growth |
| Next Earnings Release | Feb. 24, 2023 (est.) |
| Last Earnings Release | Nov. 03, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| ETCHX | 116.90M USD | 7.88% |
| LADQX | 58.14M USD | 2.24% |
| FBIOX | 92.60M USD | 1.73% |
| BTEC | 928635.0 USD | 1.59% |
| FCGSX | 86.19M USD | 0.71% |
| FGCKX | 289.36M USD | 0.68% |
| VTWG | 4.583M USD | 0.50% |
| IWO | 47.84M USD | 0.48% |
| FSSNX | 51.60M USD | 0.27% |
| VTWO | 15.11M USD | 0.25% |
| IWM | 130.34M USD | 0.24% |
| RYLD | 2.549M USD | 0.18% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| KRTX Tweets |